Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology

George S. Karagiannis, Maria P. Pavlou, Eleftherios P. Diamandis

Research output: Contribution to journalReview articlepeer-review

116 Scopus citations


Emerging proteomic tools and mass spectrometry play pivotal roles in protein identification, quantification and characterization, even in complex biological samples. The cancer secretome, namely the whole collection of proteins secreted by cancer cells through various secretory pathways, has only recently been shown to have significant potential for diverse applications in oncoproteomics. For example, secreted proteins might represent putative tumor biomarkers or therapeutic targets for various types of cancer. Consequently, many proteomic strategies for secretome analysis have been extensively deployed over the last few years. These efforts generated a large amount of information awaiting deeper mining, better understanding and careful interpretation. Distinct sub-fields, such as degradomics, exosome proteomics and tumor-host cell interactions have been developed, in an attempt to provide certain answers to partially elucidated mechanisms of cancer pathobiology. In this review, advances, concerns and challenges in the field of secretome analysis as well as possible clinical applications are discussed.

Original languageEnglish (US)
Pages (from-to)496-510
Number of pages15
JournalMolecular Oncology
Issue number6
StatePublished - Dec 2010
Externally publishedYes


  • Cancer
  • Mass spectrometry
  • Proteomics
  • Secretome

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research


Dive into the research topics of 'Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology'. Together they form a unique fingerprint.

Cite this